KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS mutations are often associated with resistance to targeted therapies and poor outcomes in patients with cancer”
From KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors (2020) · cites this paper as [2]
In the citing paper
“yet no selective KRAS inhibitor has been approved despite more than three decades of scientific effort.”
From KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors (2020) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950 · cited 1×
“0 microarray data from lung cell lines were downloaded from the National Cancer for Biotechnology Information website (GSE36133).(18) Cell line mutational status was obtained from the Sanger Institute Catalogue of Somatic Mutations In Cancer (COSMIC) Web site(9) and is shown in Supplementary Table 1 (Supplemental Digi…”
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 1×
“Mutation in the KRAS gene is one of the most frequently detected activating mutations in lung adenocarcinomas (AC).(1) KRAS mutations in lung AC usually arise at codon 12, occasionally at codon 13, and rarely at codon 61.”
Self-citationK-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 1×
“Although targeting oncogenic RAS directly has been challenging due to protein structure issues and its high affinity for GTP/GDP, a novel allosteric regulatory site has been recently identified on KRAS-G12C and small molecules that target this site have been developed.(34) In the lung cancer adjuvant setting, KRAS mut…”
Gene-expression profiles predict survival of patients with lung adenocarcinoma
Beer, D. G., Kardia, S. L. R., Huang, C.-C., Giordano, T. J., Levin, A. M., Misek, D. E., Lin, L., Chen, G., Gharib, T. G., Thomas, D. G., et al. (2002) · Nature Medicine · doi:10.1038/nm733 · Cited by 2,025
Self-citationEngelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R., Maira, M., McNamara, K., Perera, S. A., Song, Y., et al. (2008) · Nature Medicine · doi:10.1038/nm.1890 · Cited by 1,330
A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
Luo, J., Emanuele, M. J., Li, D., Creighton, C. J., Schlabach, M. R., Westbrook, T. F., Wong, K.-K., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.05.006 · Cited by 1,017
Singh, A., Greninger, P., Rhodes, D., Koopman, L., Violette, S., Bardeesy, N., & Settleman, J. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.022 · Cited by 841
Zhu, C.-Q., da Cunha Santos, G., Ding, K., Sakurada, A., Cutz, J.-C., Liu, N., Zhang, T., Marrano, P., Whitehead, M., Squire, J. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8924 · Cited by 661
Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
Riely, G. J., Kris, M. G., Rosenbaum, D., Marks, J., Li, A., Chitale, D. A., Nafa, K., Riedel, E. R., Hsu, M., Pao, W., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0646 · Cited by 578 · cited 1×
“4), as previously reported.(4) According to the amino acid substitution, the most frequent mutation was G12C (41.”
Ihle, N. T., Byers, L. A., Kim, E. S., Saintigny, P., Lee, J. J., Blumenschein, G. R., Tsao, A., Liu, S., Larsen, J. E., Wang, J., et al. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr523 · Cited by 532
Research works printed but not linked: 32
- Bos, 1989, ras oncogenes in human cancer: a review, Cancer Res, 49, 4682
- Capella, 1991, Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors, Environ Health Perspect, 93, 125, 10.1289/ehp.9193125 · DOI · Paper page
- Maus, 2014, KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies, Lung Cancer, 83, 163, 10.1016/j.lungcan.2013.11.010 · DOI
- Westra, 1996, K-ras oncogene activation in atypical alveolar hyperplasias of the human lung, Cancer Res, 56, 2224
- Li, 1994, c-k-ras and p53 mutations occur very early in adenocarcinoma of the lung, Am J Pathol, 144, 303
- Downward, 2003, Targeting RAS signalling pathways in cancer therapy, Nat Rev Cancer, 3, 11, 10.1038/nrc969 · DOI · Paper page
- Bamford, 2004, The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website, Br J Cancer, 91, 355, 10.1038/sj.bjc.6601894 · DOI · Paper page
- Garassino, 2011, Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer, Ann Oncol, 22, 235, 10.1093/annonc/mdq680 · DOI · Paper page
- Balbin, 2013, Reconstructing targetable pathways in lung cancer by integrating diverse omics data, Nat Commun, 4, 2617, 10.1038/ncomms3617 · DOI · Paper page
- Mascaux, 2005, The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis, Br J Cancer, 92, 131, 10.1038/sj.bjc.6602258 · DOI · Paper page
- Shepherd, 2013, Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy, J Clin Oncol, 31, 2173, 10.1200/JCO.2012.48.1390 · DOI · Paper page
- Goldstraw, 2006, International Staging Project. . The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer, J Thorac Oncol, 1, 281, 10.1016/S1556-0864(15)31581-1 · DOI · Paper page
- Chitale, 2009, An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors, Oncogene, 28, 2773, 10.1038/onc.2009.135 · DOI · Paper page
- Bolstad, 2003, A comparison of normalization methods for high density oligonucleotide array data based on variance and bias, Bioinformatics, 19, 185, 10.1093/bioinformatics/19.2.185 · DOI · Paper page
- Bryant, 2010, Clinically relevant characterization of lung adenocarcinoma subtypes based on cellular pathways: an international validation study, PLoS One, 5, e11712, 10.1371/journal.pone.0011712 · DOI
- Gröger, 2012, Meta-analysis of gene expression signatures defining the epithelial to mesenchymal transition during cancer progression, PLoS One, 7, e51136, 10.1371/journal.pone.0051136 · DOI · Paper page
- de Hoon, 2004, Open source clustering software, Bioinformatics, 20, 1453, 10.1093/bioinformatics/bth078 · DOI · Paper page
- Eisen, 1998, Cluster analysis and display of genome-wide expression patterns, Proc Natl Acad Sci U S A, 95, 14863, 10.1073/pnas.95.25.14863 · DOI · Paper page
- Singh, 2012, TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers, Cell, 148, 639, 10.1016/j.cell.2011.12.033 · DOI · Paper page
- Feng, 2002, Preferential DNA damage and poor repair determine ras gene mutational hotspot in human cancer, Journal Natl Cancer Inst, 94, 1527, 10.1093/jnci/94.20.1527 · DOI · Paper page
- Villaruz, 2013, The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma, Cancer, 119, 2268, 10.1002/cncr.28039 · DOI · Paper page
- Rodenhuis, 1987, Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung, N Engl J Med, 317, 929, 10.1056/NEJM198710083171504 · DOI · Paper page
- Slebos, 1990, K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung, N Engl J Med, 323, 561, 10.1056/NEJM199008303230902 · DOI · Paper page
- Andreyev, 2001, Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study, Br J Cancer, 85, 692, 10.1054/bjoc.2001.1964 · DOI · Paper page
- Angulo, 2008, Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification, J Pathol, 214, 347, 10.1002/path.2267 · DOI
- Okayama, 2012, Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas, Cancer Res, 72, 100, 10.1158/0008-5472.CAN-11-1403 · DOI · Paper page
- Planck, 2013, Genomic and transcriptional alterations in lung adenocarcinoma in relation to EGFR and KRAS mutation status, PLoS One, 8, e78614, 10.1371/journal.pone.0078614 · DOI
- Fiala, 2013, The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer, Cancer Genet, 206, 26, 10.1016/j.cancergen.2012.12.003 · DOI · Paper page
- Brugger, 2011, Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer, J Clin Oncol, 29, 4113, 10.1200/JCO.2010.31.8162 · DOI · Paper page
- Roberts, 2013, KRAS mutation: should we test for it, and does it matter?, J Clin Oncol, 31, 1112, 10.1200/JCO.2012.43.0454 · DOI · Paper page
- Sunaga, 2011, Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy, Mol Cancer Ther, 10, 336, 10.1158/1535-7163.MCT-10-0750 · DOI · Paper page
- Barbie, 2009, Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1, Nature, 462, 108, 10.1038/nature08460 · DOI · Paper page
Cited by
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
KRAS-Mutant non-small cell lung cancer: From biology to therapy
Ferrer, I., Zugazagoitia, J., Herbertz, S., John, W., Paz-Ares, L., & Schmid-Bindert, G. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.013 · Cited by 311
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0789-x · Cited by 301
“Concerning KRAS mutation subtypes, retrospective studies have shown that patients with early stage and advanced NSCLC harboring G12C KRAS mutations had significantly shorter OS compared to other KRAS mutations [66, 67].”
BackgroundSelf-citationTargeted therapy in advanced non-small cell lung cancer: current advances and future trends
Majeed, U., Manochakian, R., Zhao, Y., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01121-2 · Cited by 266
Metadata
- Authors
- Nadal, E., Chen, G., Prensner, J. R., Shiratsuchi, H., Sam, C., Zhao, L., Kalemkerian, G. P., Brenner, D., Lin, J., Reddy, R. M., Chang, A. C., Capellà, G., Cardenal, F., Beer, D. G., & Ramnath, N.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 9
- Issue
- 10
- Pages
- 1513-1522
- ISSN
- 1556-0864
- Cited by
- 113
- References
- 15
- Language
- en
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 427 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma. https://app.cochat.ai/papers/10.1097/jto.0000000000000305
- The paper
- Nadal, E., Chen, G., Prensner, J. R., Shiratsuchi, H., Sam, C., Zhao, L., Kalemkerian, G. P., Brenner, D., Lin, J., Reddy, R. M., Chang, A. C., Capellà, G., Cardenal, F., Beer, D. G., & Ramnath, N. (2014). KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma. Journal of Thoracic Oncology. https://doi.org/10.1097/jto.0000000000000305
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.